ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR676/006/SRR6762746/SRR6762746_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR676/007/SRR6762747/SRR6762747_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR676/007/SRR6762747/SRR6762747_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR676/006/SRR6762746/SRR6762746_2.fastq.gzprimaryOK200GenomicsCity University of Hong Konghttps://www.ebi.ac.uk/ena/browser/view/PRJNA433779Cas9 mRNA and sgRNA against miR125 are delivered to cancer cells by RBCEVs. After treatments, the genomic DNA of cancer cells are extracted and sent for Amplicon sequencing.xref:EuropePMC:PMC6004015ENAfalseCas9 delivered by RBCEVs against miR1252023-05-192022-01-05PRJNA433779